

Rintaro Noro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9532852/publications.pdf>

Version: 2024-02-01

53
papers

1,035
citations

430754

18
h-index

434063

31
g-index

56
all docs

56
docs citations

56
times ranked

1768
citing authors

#	ARTICLE	IF	CITATIONS
1	MiR-134/487b/655 Cluster Regulates TGF- β -Induced Epithelial-Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting <i>MAGI2</i> in Lung Adenocarcinoma Cells. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 444-453.	1.9	181
2	miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells. <i>International Journal of Oncology</i> , 2016, 48, 937-944.	1.4	66
3	Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. <i>BMC Cancer</i> , 2006, 6, 277.	1.1	54
4	Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2433-2440.	1.9	51
5	miR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma. <i>Oncology Reports</i> , 2014, 32, 2365-2372.	1.2	46
6	Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 457-461.	1.1	44
7	Urinary Metabolite Risk Biomarkers of Lung Cancer: A Prospective Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 978-986.	1.1	44
8	Histone deacetylase inhibitor enhances sensitivity of non-small cell lung cancer cells to 5-FU via down-regulation of thymidylate synthase expression and up-regulation of p21 ^{waf1/cip1} expression. <i>Cancer Science</i> , 2010, 101, 1424-1430.	1.7	40
9	Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 1052-1060.	0.8	36
10	Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema. <i>Lung Cancer</i> , 2014, 85, 258-263.	0.9	35
11	Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer. <i>Scientific Reports</i> , 2018, 8, 14896.	1.6	31
12	Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer. <i>Oncotarget</i> , 2018, 9, 27242-27255.	0.8	31
13	MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation. <i>BMC Cancer</i> , 2015, 15, 31.	1.1	29
14	Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells. <i>Thoracic Cancer</i> , 2021, 12, 1690-1698.	0.8	29
15	A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts. <i>Journal of Thoracic Oncology</i> , 2017, 12, 65-76.	0.5	26
16	Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4005.	1.8	24
17	Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis. <i>Oxford Medical Case Reports</i> , 2018, 2018, omy094.	0.2	23
18	PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. <i>International Journal of Oncology</i> , 2007, 31, 1157-63.	1.4	19

#	ARTICLE	IF	CITATIONS
19	AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier. <i>Oncology Reports</i> , 2017, 37, 3261-3269.	1.2	18
20	Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 165-173.	0.6	17
21	Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer. <i>BMC Cancer</i> , 2015, 15, 241.	1.1	16
22	Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1543-1548.	1.0	16
23	Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial (NEJ013B). <i>Thoracic Cancer</i> , 2020, 11, 1876-1884.	0.8	13
24	Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma. <i>International Journal of Oncology</i> , 2015, 46, 505-512.	1.4	12
25	Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression. <i>Anticancer Research</i> , 2018, 38, 753-762.	0.5	12
26	Prognostic significance of ABCB1 in stage I lung adenocarcinoma. <i>Oncology Letters</i> , 2017, 14, 313-321.	0.8	10
27	A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5879-5883.	1.0	10
28	Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 2142-2151.	0.8	10
29	Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report. <i>BMC Research Notes</i> , 2015, 8, 165.	0.6	9
30	Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report. , 2019, 7, 59.		9
31	Tenascin XB Is a Novel Diagnostic Marker for Malignant Mesothelioma. <i>Anticancer Research</i> , 2019, 39, 627-633.	0.5	9
32	Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5601-5605.	1.0	7
33	Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed. <i>International Journal of Oncology</i> , 2014, 44, 1886-1894.	1.4	6
34	Interstitial lung disease associated with amrubicin chemotherapy in patients with lung cancer: a single institutional study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 674-680.	0.6	6
35	Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer. <i>Internal Medicine</i> , 2021, 60, 591-594.	0.3	6
36	A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed. <i>Anticancer Research</i> , 2022, 42, 709-722.	0.5	6

#	ARTICLE	IF	CITATIONS
37	A Drug Interaction between Crizotinib and Warfarin in Non-Small-Cell Lung Cancer: A Case Report. <i>Journal of Nippon Medical School</i> , 2017, 84, 291-293.	0.3	5
38	Drifting EGFR mutation. <i>Chinese Clinical Oncology</i> , 2013, 2, 3.	0.4	5
39	Phase II study of carboplatin+paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: H0T1201/NEJ024. <i>International Journal of Clinical Oncology</i> , 2022, , 1.	1.0	3
40	Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma. <i>Molecular and Clinical Oncology</i> , 2022, 16, 87.	0.4	3
41	The respiratory microbiome associated with chronic obstructive pulmonary disease comorbidity in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, , .	0.8	3
42	Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 659-667.	1.0	2
43	Eczematous reactions mimicking psoriasiform dermatitis induced by nivolumab for advanced lung cancer. <i>Australasian Journal of Dermatology</i> , 2019, 60, e67-e68.	0.4	2
44	The Anticancer Effect of Histone Deacetylase Inhibitors and Combination with the Cytotoxic Agents in Lung Cancer Cells: Biological Analyses for Future Clinical Application. <i>Journal of Nippon Medical School</i> , 2009, 76, 44-46.	0.3	2
45	ACTN4 gene amplification is a predictive biomarker for adjuvant chemotherapy with UFT in stage I lung adenocarcinomas. <i>Cancer Science</i> , 2021, , .	1.7	2
46	Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 5315-5319.	1.0	2
47	PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma. <i>Anticancer Research</i> , 2021, 41, 2501-2509.	0.5	1
48	CADM1 and SPC25 gene mutations in lung cancer patients with idiopathic pulmonary fibrosis. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100232.	0.6	1
49	Phase II study of efficacy of bevacizumab plus chemotherapy in management of malignant pleural effusion (MPE) in non-squamous non-small cell lung cancer (NSCLC) patients with MPE unsuccessfully controlled by tube drainage or pleurodesis (North East Japan Study Group Trial) Tj ETQq1 1 0.784314. <i>igBT /Overlock 1</i>	0.8	1
50	Two cases of superior mesenteric artery syndrome during chemotherapy in patients with lung cancer. <i>International Cancer Conference Journal</i> , 2022, 11, 124-128.	0.2	1
51	BIWEEKLY ADMINISTRATION OF IRINOTECAN (CPT-11) PLUS CISPLATIN WITH AN ANTIDIARRHEAL PROGRAM OF INTESTINAL ALKALIZATION TO REDUCE DIARRHEA IN CANCER PATIENTS. <i>Annals of Cancer Research and Therapy</i> , 2012, 20, 52-57.	0.1	0
52	Possible utility of actinin-4 as a predictive biomarker of the efficacy of postoperative adjuvant chemotherapy for completely resected early stage lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20003-e20003.	0.8	0
53	A Case of Metastasis to Ovarian Tumor from Pulmonary Large-cell Neuroendocrine Carcinoma. <i>Japanese Journal of Lung Cancer</i> , 2019, 59, 88-93.	0.0	0